Citations

Clear

4610 citation(s) found for "Lu, Brian".

Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects
Samadzadeh, Sara , Olesen, Mads Nikolaj , Wirenfeldt, Martin , Möller, Sören , Misu, Tatsuro , Soelberg, Kerstin , Frederiksen, Jette Lautrup , Ruprecht, Klemens , Andersen, Thomas Levin , Marignier, Romain , Lillevang, Søren Thue , Pittock, Sean J, Kim, Ho Jin , Bennett, Jeffrey L. , Paul, Friedemann , Sørensen, Grith Lykke , Weinshenker, Brian G. , Pittock, Sean J. , Pittock, S J , Marignier, Romain , Flanagan, E P , Pittock, Sean J , Kim, Ho Jin , Bennett, Jeffrey L , Weinshenker, Brian G , Paul, Friedemann , Heegaard, Steffen , Mariotto, Sara , Fujihara, Kazuo , Flanagan, Eoin P. , Lassmann, Hans , Asgari, Nasrin

Mayo Clinic

Multiple Sclerosis Journal | October 13, 2023 | Volume: 29 | Issue: 14 | Pages: 1721-1735

10.1177/13524585231200720 | PMID 37830484 Get It

Background: Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein not previously described in the human central nervous system (CNS). Objectives: We determined MFAP4 CNS expression and measured cerebrospinal fluid (CSF) and serum levels. Methods: Tissue was sampled at autopsy from patients with acute multiple sclerosis (MS) ( n = 3), progressive MS ( n = 3), neuromyelitis optica spectrum disorder (NMOSD) ( n = 2), and controls ( n = 9), including 6 healthy controls (HC). MFAP4 levels were measured in 152 patients: 49 MS, 62 NMOSD, 22 myelin oligodendrocyte glycoprotein-associated disease (MOGAD), and 19 isolated optic neuritis (ION). Results: MFAP4 localized to meninges and vascular/perivascular spaces, intense in the optic nerve. At sites of active inflammation, MFAP4 reactivity was reduced in NMOSD and acute MS and less in progressive MS. CSF MFAP4 levels were reduced during relapse and at the onset of diseases (mean U/mL: MS 14.3, MOGAD 9.7, and ION 14.6 relative to HC 17.9. ( p = 0.013, p = 0.000, and p = 0.019, respectively). Patients with acute ON ( n = 68) had reduced CSF MFAP4 (mean U/mL: 14.5, p = 0.006). CSF MFAP4 levels correlated negatively with relapse severity (rho = −0.41, p = 0.017). Conclusion: MFAP4 immunoreactivity was reduced at sites of active inflammation. CSF levels of MFAP4 were reduced following relapse and may reflect disease activity.
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, Edward M. , Srinivas, Sandy, An, Yi , Barocas, Daniel A. , Bitting, Rhonda L. , Bryce, Alan H. , Chapin, Brian F. , D’Amico, Anthony V. , Desai, Neil , Dorff, Tanya B. , Eastham, James A., Farrington, Thomas A., Gao, Xin , Gupta, Shilpa , Guzzo, Thomas, Kuettel, Michael, McKay, Rana R. , Morgan, Todd M. , Pow‐Sang, Julio M. , Reiter, Robert E. , Roach, Mack , Rosenfeld, Stan, Shabsigh, Ahmad , Valicenti, Richard K., Wong, J.K. , Shead, Dorothy A. , Snedeker, Jenna, Freedman-Cass, Deborah A., Bryce, Alan, Bryce, Alan H , Morgan, Todd M , Robin, Tyler P. , Adra, Nabil , Cheng, Heather H. , Ippolito, Joseph E. , Lang, Joshua M. , Lotan, Tamara Levin , Netto, George J. , Spratt, Daniel E. , Teply, Benjamin A. , Tward, Jonathan D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 12, 2023 | Volume: 21 | Issue: 10 | Pages: 1067-1096

10.6004/jnccn.2023.0050 | PMID 37856213 Get It

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment intensification is strongly recommended for patients with metastatic castration-sensitive prostate cancer. For patients with nonmetastatic CRPC, ADT is continued with or without the addition of certain secondary hormone therapies depending on prostate-specific antigen doubling time. In the mCRPC setting, ADT is continued with the sequential addition of certain secondary hormone therapies, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, the presence or absence of visceral disease, symptoms, and potential side effects.
Executive Summary: Guidelines for Evaluating New Fever in Adult Patients in the ICU
O’Grady, Naomi P., Alexander, Earnest, Alhazzani, Waleed , Alshamsi, Fayez , Cuellar‐Rodríguez, Jennifer , Jefferson, Brian , Patel, Robin , Deresinski, Stanley C. , Patel, Robin , Kalil, André C. , Pastores, Stephen M. , van Duin, David , Weber, David J.

Mayo Clinic

Critical Care Medicine | October 12, 2023 | Volume: 51 | Issue: 11 | Pages: 1566-1569

10.1097/ccm.0000000000006021 | PMID 37902339 Get It

P‐TA‐3 | Characterization of Spirometric Response to Therapeutic Plasma Exchange (TPE) and Factors Associated with Respiratory Distress in Myasthenia Gravis Patients
Weli, Homayemem , Fortuny, Lisandro, Shah, Palmi , Hernández, P , Kneiber, Diana , Stamos, Alex, Varadhachary, Atul , Sommerville, R. Brian, Despotis, Grigorios, OʼBrien, Jennifer , Hernandez, P., Kneiber, D., Stamos, A., Varadhachary, A.

Mayo Clinic

Transfusion | October 12, 2023 | Volume: 63 | Issue: S5 | Pages: No page available

10.1111/trf.327_17554 Get It

Society of Critical Care Medicine and the Infectious Diseases Society of America Guidelines for Evaluating New Fever in Adult Patients in the ICU
O’Grady, Naomi P., Alexander, Earnest, Alhazzani, Waleed , Alshamsi, Fayez , Cuellar‐Rodríguez, Jennifer , Jefferson, Brian , Patel, Robin , Deresinski, Stanley C. , Patel, Robin , Kalil, André C. , Pastores, Stephen M. , van Duin, David , Weber, David J.

Mayo Clinic

Critical Care Medicine | October 12, 2023 | Volume: 51 | Issue: 11 | Pages: 1570-1586

10.1097/ccm.0000000000006022 | PMID 37902340 Get It

RATIONALE: Fever is frequently an early indicator of infection and often requires rigorous diagnostic evaluation. OBJECTIVES: This is an update of the 2008 Infectious Diseases Society of America and Society (IDSA) and Society of Critical Care Medicine (SCCM) guideline for the evaluation of new-onset fever in adult ICU patients without severe immunocompromise, now using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. PANEL DESIGN: The SCCM and IDSA convened a taskforce to update the 2008 version of the guideline for the evaluation of new fever in critically ill adult patients, which included expert clinicians as well as methodologists from the Guidelines in Intensive Care, Development and Evaluation Group. The guidelines committee consisted of 12 experts in critical care, infectious diseases, clinical microbiology, organ transplantation, public health, clinical research, and health policy and administration. All task force members followed all conflict-of-interest procedures as documented in the American College of Critical Care Medicine/SCCM Standard Operating Procedures Manual and the IDSA. There was no industry input or funding to produce this guideline. METHODS: We conducted a systematic review for each population, intervention, comparison, and outcomes question to identify the best available evidence, statistically summarized the evidence, and then assessed the quality of evidence using the GRADE approach. We used the evidence-to-decision framework to formulate recommendations as strong or weak or as best-practice statements. RESULTS: The panel issued 12 recommendations and 9 best practice statements. The panel recommended using central temperature monitoring methods, including thermistors for pulmonary artery catheters, bladder catheters, or esophageal balloon thermistors when these devices are in place or accurate temperature measurements are critical for diagnosis and management. For patients without these devices in place, oral or rectal temperatures over other temperature measurement methods that are less reliable such as axillary or tympanic membrane temperatures, noninvasive temporal artery thermometers, or chemical dot thermometers were recommended. Imaging studies including ultrasonography were recommended in addition to microbiological evaluation using rapid diagnostic testing strategies. Biomarkers were recommended to assist in guiding the discontinuation of antimicrobial therapy. All recommendations issued were weak based on the quality of data. CONCLUSIONS: The guidelines panel was able to formulate several recommendations for the evaluation of new fever in a critically ill adult patient, acknowledging that most recommendations were based on weak evidence. This highlights the need for the rapid advancement of research in all aspects of this issue—including better noninvasive methods to measure core body temperature, the use of diagnostic imaging, advances in microbiology including molecular testing, and the use of biomarkers.
Comparative cost-effectiveness of contemporary treatment strategies for stage IIA seminoma
Sharma, Vidit , Wymer, Kevin , Walia, Arman, Costello, Brian A. , Pagliaro, Lance C. , Daneshmand, Siamak , Leibovich, Bradley C. , Boorjian, Stephen A. , Joyce, Daniel D , Moriarty, James P. , Pagliaro, Lance C , Daneshmand, Siamak , Boorjian, Stephen A , Joyce, Daniel , Borah, Bijan J.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 11, 2023 | Volume: 116 | Issue: 3 | Pages: 468-475

10.1093/jnci/djad211 | PMID 37819776 Get It

Abstract Background The Surgery in Early Metastatic Seminoma (SEMS) trial examined retroperitoneal lymph node dissection as first-line treatment for patients with isolated 1-3 cm retroperitoneal lymphadenopathy. To date, the standard of care for these patients has been either chemotherapy or radiotherapy. Herein, we evaluated the relative cost-effectiveness of these management strategies. Methods A microsimulation model assessed the cost-effectiveness of retroperitoneal lymph node dissection, chemotherapy, and radiotherapy for stage IIA seminoma. Sensitivity analyses were performed to evaluate model robustness. Retroperitoneal lymph node dissection recurrence probabilities were obtained from the SEMS trial. All other probability and utility values were obtained from published literature. Primary outcomes included costs from a commercial insurer’s perspective, effectiveness (quality adjusted life-years [QALYs]), and incremental cost-effectiveness ratios using a willingness-to-pay threshold of $100 000/QALY. Results At a lifetime horizon, the mean costs per patient for retroperitoneal lymph node dissection, radiotherapy, and chemotherapy were $58 469, $98 783, and $104 096, and the mean QALYs were 40.61, 40.70, and 39.15, respectively. Retroperitoneal lymph node dissection was found to be the most cost-effective approach because of high costs and accrued disutility of chronic toxicities associated with radiotherapy (cost-effectiveness ratios = $433 845/QALY) and chemotherapy (dominated). On 1-way sensitivity analyses, retroperitoneal lymph node dissection was no longer cost-effective if the probabilities of infertility and cardiovascular toxicity after radiotherapy were less than 13% and 16%, respectively, or if the 2-year probability of progression after retroperitoneal lymph node dissection was more than 26%. Conclusions Retroperitoneal lymph node dissection was the most cost-effective treatment approach for stage IIA seminoma. These findings support clinical guideline consideration of including retroperitoneal lymph node dissection as a treatment option for well-selected patients with stage IIA seminoma.
Abstract 037: Neuromodulation Of Adipocyte Activity In Perivascular Adipose Tissue In Healthy Mice
Morales‐Soto, Wilmarie , Gulbransen, Brian D. , Hanscom, Marie , Jackson, William F.

Mayo Clinic

Hypertension | October 11, 2023 | Volume: 80 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.80.suppl_1.037 Get It

Perivascular adipose tissue (PVAT) has emerged as a regulator of blood pressure by releasing anticontractile factors, which may be disrupted in disease. The production of adipocyte anticontractile factors is driven by norepinephrine (NE), a sympathetic neurotransmitter; however, the source of NE remains unknown. Here, we tested the hypothesis that neuronal innervation of PVAT stimulates adipocytes via NE. Mesenteric (mPVAT), aortic (aPVAT), and subcutaneous fat (sc) depots were studied in healthy male and female mice aged 8-12 weeks. Immunostaining with neuronal and vasculature markers was performed to assess anatomical evidence of neural innervation (n=3 region/sex). Adipocyte activity was studied in Adiponectin Cre;GCaMP 5g-tdT mice, which express the calcium indicator GCaMP5g in adipocytes (125-350 cells/group). Adipocytes were challenged with NE, a parasympathomimetic (bethanechol, 10uM, bath application), and nerve fibers were activated by electrical field stimulation (EFS; +100V, 0.1ms, 10 Hz). Immunolabeling data show that nerve fibers run adjacent to the larger blood vessels within adipose tissue, rather than radiating throughout. Stimulation with NE induced large responses (female: 0.91±0.73, 1.15±0.73, 1.45±0.9 dF/F 0 ; male: 0.75±0.57, 1.01±0.78, 0.73±0.53 dF/F 0 in aPVAT, mPVAT, sc, respectively). Both the parasympathomimetic and EFS induced minimal adipocyte responses compared to NE (% NE = [dF/F 0 bethanechol or EFS / dF/F 0 NE]*100%; bethanechol - female: 39.5%, 13.9%, 9.7%, male: 24.0%, 14.6%, 15.1% in aPVAT, mPVAT, sc, respectively; EFS - female: 31%, 12.2%, 9.7%, male: 28%, 13.9%, 13.7% in aPVAT, mPVAT, sc, respectively). These findings suggest that neural innervation within the PVAT, and functional regulation of adipocytes, is limited. Nerve fibers present within the PVAT are not the primary source of NE driving adipocyte production of anticontractile factors in the PVAT. Rather, this NE originates from other mechanisms including local production by non-neuronal cells or circulation of neurotransmitters.
Risk of Monopolar Electrosurgery in Cochlear Implant Recipients is Nominal: Evidence to Guide Clinical Practice
Dornhoffer, James R. , Haller, Travis J. , Lohse, Christine M. , Driscoll, Colin L. W., Neff, Brian A., Saoji, Aniket A. , Carlson, Matthew L. , Haller, Travis

Mayo Clinic

Otolaryngology–Head and Neck Surgery | October 9, 2023 | Volume: 170 | Issue: 2 | Pages: 505-514

10.1002/ohn.555 | PMID 37811571 Get It

AbstractObjectiveComprehensively assess the prevalence of monopolar electrosurgery‐related device complications among cochlear implant (CI) recipients.Study DesignMultifaceted retrospective review and survey.SettingTertiary medical center.MethodsMultifaceted approach including: (i) review of the current literature; (ii) historical review of institutional data from an academic, tertiary CI center; (iii) review of industry data provided by 3 Food and Drug Administration‐approved CI manufacturers; and (iv) survey of high‐volume CI centers.ResultsLiterature review identified 9 human studies, detailing 84 devices with 199 episodes of device‐cautery exposure. From studies reporting on patients records, no implant showed evidence of damage after exposure. One cadaveric study using dental cautery reported 1 episode of device damage. Review of institutional records did not identify any CI damage in 84 instances of exposure. Data from the 3 major implant manufacturers showed a single report of damage that could be reasonably linked to monopolar electrosurgery, out of a possible 689,426 CIs. Last, a survey of 8 high‐volume CI centers did not identify any adverse events associated with monopolar cautery.ConclusionThese data estimate the risk of adverse device‐related events or tissue injury to be extraordinarily low. Short of operating in immediate proximity to the CI (ie, the ipsilateral temporoparietal scalp), these data indicate that monopolar electrosurgery can be used in the body and the head‐and‐neck of CI recipients with nominal risk. These findings may guide decision‐making in cases that are optimally or preferably performed with monopolar electrocautery and can be used to counsel CI patients following inadvertent exposures.
Electrocardiographic spiked-helmet sign in critical non-cardiac illness
Narvaez‐Guerra, Offdan , Osorio, Brian, Gentile, Bryon A. , Munoz, Freddy Del‐Carpio , Del-Carpio Munoz, Freddy

Mayo Clinic

BMJ Case Reports | October 9, 2023 | Volume: 16 | Issue: 10 | Pages: e254546

10.1136/bcr-2022-254546 | PMID 37813557 Get It

The spiked-helmet sign (SHS) is an electrocardiographic finding characterised by a distinctive pattern associated with critical illness, resolving once the clinical condition improves. While the underlying mechanism remains uncertain, different mechanisms have been proposed to account for these findings including changes in intrathoracic or intra-abdominal pressures, transient compression of the coronary arteries, repolarisation abnormalities and electromechanical artefacts. We describe the development of the SHS in a patient with underlying left bundle branch pacing following the development of respiratory failure due to haemoptysis and review proposed mechanisms for its pathophysiology.
Synthesizing images of tau pathology from cross-modal neuroimaging using deep learning
Lee, Jeyeon , Burkett, Brian J. , Min, Hoon‐Ki , Dicks, Ellen , Corriveau‐Lecavalier, Nick , Mester, Carly , Wiste, Heather J. , Murray, Melissa E. , Nguyen, Aivi T. , Reichard, Ross R., Graff‐Radford, Jonathan , Barnard, Leland R , Gunter, Jeffrey L. , Kantarci, Kejal , Lowe, Val J. , Petersen, Ronald C. , Jack, Clifford R. , Corriveau-Lecavalier, Nick , Mester, Carly T, Lundt, Emily S. , Murray, Melissa E , Botha, Hugo , Graff-Radford, Jonathan , Schwarz, Christopher G , Kantarci, Kejal , Knopman, David S. , Boeve, Brad , Jack, Clifford R , Jones, David T , Min, Hoon-Ki Paul , Nguyen, Aivi T , Burkett, Brian , Senjem, Matthew L. , Botha, Hugo , Schwarz, Christopher G. , Knopman, David S. , Boeve, Bradley F. , Jones, David T.

Mayo Clinic

Brain | October 7, 2023 | Volume: 147 | Issue: 3 | Pages: 980-995

10.1093/brain/awad346 | PMID 37804318 Get It

Abstract Given the prevalence of dementia and the development of pathology-specific disease-modifying therapies, high-value biomarker strategies to inform medical decision-making are critical. In vivo tau-PET is an ideal target as a biomarker for Alzheimer’s disease diagnosis and treatment outcome measure. However, tau-PET is not currently widely accessible to patients compared to other neuroimaging methods. In this study, we present a convolutional neural network (CNN) model that imputes tau-PET images from more widely available cross-modality imaging inputs. Participants (n = 1192) with brain T1-weighted MRI (T1w), fluorodeoxyglucose (FDG)-PET, amyloid-PET and tau-PET were included. We found that a CNN model can impute tau-PET images with high accuracy, the highest being for the FDG-based model followed by amyloid-PET and T1w. In testing implications of artificial intelligence-imputed tau-PET, only the FDG-based model showed a significant improvement of performance in classifying tau positivity and diagnostic groups compared to the original input data, suggesting that application of the model could enhance the utility of the metabolic images. The interpretability experiment revealed that the FDG- and T1w-based models utilized the non-local input from physically remote regions of interest to estimate the tau-PET, but this was not the case for the Pittsburgh compound B-based model. This implies that the model can learn the distinct biological relationship between FDG-PET, T1w and tau-PET from the relationship between amyloid-PET and tau-PET. Our study suggests that extending neuroimaging’s use with artificial intelligence to predict protein specific pathologies has great potential to inform emerging care models.